earnings first afternoon joining Good XXXX for quarter update. for and thank you our us
quarter first The been and for a has one busy productive Capricor.
men in I trial young with the otherwise the of clinical initiation important and investigating muscular DMD. most is as dystrophy thing CAP-XXXX HOPE-X of and will talk Duchenne first today about known The use our boys
will which current potentially one later that HOPE-X treated are trial process hoping also for enroll the a first for stages important the immunomodulatory therapies it may specifically now no and have very DMD pivotal targeting been for and of the patients because disease first trial briskly. an treatment The exist. be is we trial the
clinical XX nine remind could we but that that with criteria and or need most clinicaltrials.gov stages only last four boys inability think well This are DMD. XXX highlights to on advance in later have randomized is to huge placebo-controlled to this [emulate] medical inclusion initiatives potentially stage over progression up delighted HOPE-X the those you The were me patient there a something available attenuate all. double-blind, of I DMD men looked When important the and population were that trial the is DMD. Let to will enroll at Capricor unmet in that at we patients. of
One goals my patients need their working endpoints development with since the was in community. tune of Biotechnology sit DMD therapeutics of in the Duchenne and DMD. of program Council to which develop to families with to FDA to order DMD to their we now the on become I clinical involved fine the the tailor for our began is
this is of is their motorized is the accepted of many way and PPMD become our transport have organizations represents as necessary eager of that day increasingly are back was recently which them on Project log] [path life, feet. of the use at their by and Dystrophy issues to reflected for presented which maintaining independence. the non-ambulatory the research has patients get that not data in what advocacy One the is for of their Parent relevant Muscular clear They and hands absolutely arms, to
dose that we patients. efficacy in in potentially point motivated This more earlier for achieve measures eat, maintaining community a wheelchairs, of development arms and is this over goal if groom goal significant believe they we the and improvement With the towards become see value stated can therapies has this drink end can level they the in the treatment DMD may and of HOPE-X their their arm to use the hand primary first class this of strength. of then have control be We hands as independence in very these and to themselves. are and is via cannot here the this a our trial distal simple most HOPE-X patients that million intravenous trial. is we end the you receive their In of and the of level, months within that know reach arms. data of mid community and our fall every compelling limb and cells performance three the of will we may remember, of from improvement one outcome in was upper pre-specified Duchenne HOPE-X DMD see hands pieces as a HOPE the the or delivered points an the now use delivery. of XXX excited
more So to cells shown maximize frequently and have it easily patients. that cells this we be to therapies far, that more have that and the with effect minimal we it or the IV deliver the also inconvenience been the adoptable delivered we pre-clinically so deliver design could We way do and of discomfort a CAP-XXXX. as platform way. Using trials easily can the can
as to Now delivery did conclude we in a how to few I to minutes it explain that HOPE therapeutic the the delivering we intra-corner cells using deliver we the Duchenne. would take benefit opposed same that IV can like
that the with paradigm. treadmill we the the commonly in mouse that that muscular is improvements to genetic we observations is of and experiments into MDx dystrophy the MDx and delivered saw Remember, pre-clinically cells the heart. on running in their significant mice market of used was model therapeutic One early made treated build
recently evidenced cells of where a capable dystrophin the It cells conclusion the muscle accepted muscle. their the This site is So, of very was form [lung] of an the skeletal which In cells well somehow sensitive were the muscle travel exosomes followed be has degeneration these repair. of have of stimulating to benefit the muscle the due which intracoronary paradigm the the safety studies series of to the death bio-distribution shows immunomodulatory exosomes, have to to steroids signals the going simple injury. cells also amount to a tremendous the minimal to or so their had although shown inflammation with inflammation endogenous directly DMD that and inflammation deficiency a also a showed heart derive the one CAP-XXXX to both But led of is delivered is the there new in is one started profound been effect entirely that observation experiments delivery. that up for can from therapeutic that this the of immediately extracellular to is just is that by disease. to other both transmitted Muscle disease or muscle We into benefit the fibrosis. by lead and to of inflammation vesicles pre-clinical diseases progression or no and were using same the investigations due enough. DMD strongly of is we heart, repairs greatly accelerated responding the IV that risk. standard suited itself of treatment circulation where that delivered not is which on as released well capacity, inflammation. microvascular were of to and Then This then first were a suppression
muscle engraft, build released defining which journey that their well executed of response. but has the and that spent the model to primary scientific not as have action carefully two the to factors, do cytokines a exosomes the the CAP-XXXX. investigation heart injury years of been last and mechanism planned us allowed the immune where rather of cells includes of the travel skeletal has as further and We shows of growth muscles of muscle that is mode action site that modulation It
action. CAP-XXXX's specifically believe the let of So, how explain mechanism me we exosomes mediate
well have been DNA. the showing the to happen. MX MX angry with does is about CDCs that exosomes know and for is how fibers] ask as non-coding cocktail state. an But as inflammatory exosomes which are Y published which last pro-healing such As of talking RNA shift anti-inflammatory micro preclinical have for state proteins can from in some we that years data RNAs [macro we a We unique the RNA, two filled as
observed of important can by While understand showed why very now potent RNAs micro for it’s which just potency, of the because assays. in measured circle IFCT that now as work potency can biologically have manufacture us from for injured very lead which MX clear to also cellular at that Cell three The which non-potent mediate the three we is that presented promotes data micro muscles. modulation of banks this discovery critical in cells data impact can which immune are our MX Canada contained have years data and the determine will cells exosomes healing very Society between this cause in we transition alterations the the effects important is the cell of This we we which are will cells Montreal, we we or Transplantation but versus cells the of response importantly, work. and now that week complete. RNAs can to levels made differentiate can more that International a active last cell banks our predict this the ability and to they
HOPE-X. we is me be believe the trials banks encouraging can clinical Let HOPE-X which have just to our criteria all positive the to of results in see used that that from say cell potency me
a time talk to exosome about program. little is good our a this Now bit
from You've let exosomes are from the unique you heard me few for talk other CDCs that years a me now, are excitement exosomes. made remind about exosomes our and with
CDC IFCT have exosomes better the team. instance but which MFC have head different for been they not presented of contents tested every exosome our are only and by comparisons again as to know at week We last exosome worked and have in run to CDC head in that circumstance we
very to muscular carefully the beating bodies, our heart on immunomodulation its unique of In So, do requires CDC [indiscernible] naturally from that exosome. than heart. type only in now an patients until are per we XX,XXX there privilege, have and look come year cases organs. organ, metastasis in stage which at people in autopsy shows repair always who those not had consider the the analysis In infection is the tissue out goes one to the the unique bacteria early only rare. in cancer. on is sees heart source and that from heart very order or Male of late be other clinic or published and as breath, better bacterial does X also cardiac add male job occurring [indiscernible] is of the every case about last they let’s A all but which very circulation a tissue it in cancer it rarely viral very, either stick Despite it on through rare the by fact that be immune exosome heart, recent is study at a fact that that that extremely virus our are our the the is to why another to might well. around, almost
this heart our that is expansions naturally the other heart. cells] corresponding [these with when protection elsewhere believe and are important the CDCs this type mediate that why isolation they so proprietary response. dose and we the processes, repair can body. the exosomes large CDC occurring the protect in Now words, Using immune potentially their deliver exosomes? In we are can of in make targeted modulate discussing cells to We and
cells that We with investigating dystrophy. Duchenne in muscular are now the
we company one cells DMD. know focused, with you of is success as a small principles to done the remain and So, of in have the that
clinical Now that of action, the of enrolling indications we are we on the is understanding use well, indication managing team and of greater select our that armed their are to to and focus exosomes prime or can with that development that. now mechanism HOPE-X now in we which is the best a
deepened research leaders rare as the narrowing have fibrosis. medical select primary meet is with and The There so many the and of are with one criteria, pathological and developing target a to and consequences internal one in criteria key process need opinion teams conditions groups We a inflammation we require disease the right which one that our field we disease. of are should unmet and soon. these currently high the
the for seems in we course very to clinic regulatory the which to be happy the say, Now subject have for been I'm of the approval. formulation background, also working on to ready exosomes,
well as also have an cell helps quality of move and exosomes immortalized stay goods tuned line been make lyophilize to with them our as We as cost we the exosome Please significantly. which program from attributes forward. able reducing sold
derived the are to are we that We enter can of bringing and possibility the excited about have keenly without the At the regenerative space, Capricor, were that exosomes be to first to medicine cells exosomes the so the exosomes the we meeting of one the aware benefits clinic. cells. the potential the of revolutionize solid
we can are as announcement you XXXX. exosomes breakthrough development Thank you clinical go as with I to planned see, FDA, indication it the milestones time. therapy, well such update other for over exciting the days as of meetings many as therapies an for breakthrough these financials. look on to So, milestones that's and the HOPE-X plan a for cell enrollment, AJ back you over to for AJ. Capricor to of forward continuing will such turn and for designation our our your
